These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
4. Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects. Pender MP; Wolfe NP Intern Med J; 2002 Nov; 32(11):554-63. PubMed ID: 12412939 [TBL] [Abstract][Full Text] [Related]
5. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in multiple sclerosis, Part 2. Becker CC; Gidal BE; Fleming JO Am J Health Syst Pharm; 1995 Oct; 52(19):2105-20; quiz 2132-4. PubMed ID: 8535945 [TBL] [Abstract][Full Text] [Related]
8. The treatment of multiple sclerosis: current and future. Polman CH; Hartung HP Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119 [TBL] [Abstract][Full Text] [Related]
9. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related]
10. Newer versus older treatments for relapsing-remitting multiple sclerosis. Weinstock-Guttman B; Cohen JA Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapies in neurologic disorders. Graves D; Vernino S Med Clin North Am; 2012 May; 96(3):497-523, x. PubMed ID: 22703853 [TBL] [Abstract][Full Text] [Related]
12. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes. Frohman EM; Racke M; van Den Noort S Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973 [No Abstract] [Full Text] [Related]
13. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Clegg A; Bryant J; Milne R Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743 [No Abstract] [Full Text] [Related]
15. Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies--an update. Donoghue S; Greenlees C Expert Opin Investig Drugs; 2000 Jan; 9(1):167-71. PubMed ID: 11060669 [TBL] [Abstract][Full Text] [Related]
16. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S; Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241 [No Abstract] [Full Text] [Related]
18. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
19. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Weiner HL; Cohen JA Mult Scler; 2002 Apr; 8(2):142-54. PubMed ID: 11990872 [TBL] [Abstract][Full Text] [Related]
20. Key issues in the diagnosis and treatment of multiple sclerosis. An overview. O'Connor P; Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786 [No Abstract] [Full Text] [Related] [Next] [New Search]